Celltrion confirms neutralising potency against emerging SARS-CoV-2 variants with anti-COVID-19 monoclonal antibody treatment regdanvimab (CT-P59)

Must Read

Celltrion Group today announced that CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate, has confirmed neutralising potency against emerging variants first identified in New York (B.1.526), Nigeria (B.1.525) and …

Latest News

BPOM partners with 187 universities to boost ATMP ecosystem

Jakarta (ANTARA) - The Indonesian Food and Drug Authority (BPOM) has partnered with 187 top domestic universities to boost...

More Articles Like This